<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18169">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696110</url>
  </required_header>
  <id_info>
    <org_study_id>SYNH20120001</org_study_id>
    <secondary_id>2011BAI11B07</secondary_id>
    <nct_id>NCT01696110</nct_id>
  </id_info>
  <brief_title>Bivalirudin foR Acute Myocardial Infarction underGoing Angioplasty in CHinese patienTs.</brief_title>
  <acronym>BRIGHT</acronym>
  <official_title>Bivalirudin for Acute Myocardial Infarction Undergoing Angioplasty in Chinese Patients: a Randomized, Single-blind, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jing'an District People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fu Wai Hospital, Beijing, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sino-Japanese Friendship Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daqing Oil Field Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zunyi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lanzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanchang Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cangzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bethune International Peace Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Institute of Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenyang Shen Zhou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yingkou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Meihekoushi Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Beijing PLA Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Yuncheng Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Luhe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningxia Hui Autonomous Region Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nankai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin TEDA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study would enrolled a total of 2100 AMI patients undergoing PCI to one of three
      antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone, or
      unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor.

      All enrolled patients would be followed-up to 30 days, 6 months, and 1 year. The purpose of
      the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single-blind, active drug controlled multicenter clinical
      research and the study would enrolled a total of 2100 AMI patients undergoing percutaneous
      coronary intervention (PCI) to one of three antithrombotic regimens: bivalirudin alone, or
      unfractionated heparin alone, or unfractionated heparin plus a glycoprotein IIb/IIIa
      inhibitor. All enrolled patients would be followed-up to 30 days, 6 months, and 1 year. The
      purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients
      with DES.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Acute Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.</description>
    <other_name>Taijianing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 80 years old

          -  Male or female

          -  Plan to underwent emergency PCI in patients with acute myocardial infarction
             (including: type st-elevation myocardial infarction and the non st-elevation
             myocardial infarction), STEMI onset 12 hours or less (or the 12 to 24 hours still
             have chest pain or discomfort and continuous st elevation or new happening LBBB
             patients, NSTEMI within 72 hours for the complete PCI;

          -  Try to avoid 30 days to the myocardial infarction criminals vascular other target
             lesion revascularization completed (if for non-medical reasons plan for other target
             lesion reascularization, need to be related to the registration perioperative
             antithrombotic drug and PCI process, and the perioperative antithrombotic drugs must
             be consistent to the previous PCI, such as heparin, or heparin plus tirofiban ,or
             bivalirudin).

          -  Before PCI specification antiplatelet drugs agreed to participate in the clinical
             test and preoperative sign written informed consent.

        Exclusion Criteria:

          -  Have the following situations one of shall be excluded, not in the CARDS:

               1. anticipation (clinical manifestations or coronary CT examination such as tip) or
                  by coronary arteriography (CAG) judgment is not GeHang PCI person; Treatment by
                  thrombolysis within 72 hours of acute st-elevation type myocardial infarction,
                  left main coronary artery disease, cardiogenic shock patients;

               2. Preoperative 48 hours were used for class, heparin/low molecular heparin,
                  warfarin, etc of anticoagulant drugs or than cutting LuDing patients
                  elimination;

               3. Active bleeding or bleeding constitution, bleeding tendency person, including
                  the recent retina or vitreous hemorrhage (1 months), digestive tract and urinary
                  tract hemorrhage (3 months), cerebral hemorrhage (6 months) and cerebral
                  infarction history (3 months), etc.;

               4. With larger may lead to vascular lesions and secondary bleeding factors (such as
                  active gastric ulcer, active ulcerative colitis, intracranial aneurysm, etc.),

               5. Nearly a month have deep puncture and major surgery history (including eye or
                  brain surgery) person;

               6. Suspicious aortic dissection, pericarditis and subacute bacterial endocarditis;

               7. Has nothing to do with the treatment of uncontrolled hypertension &gt; 180/110 MMHG

               8. Routine blood anomaly (hemoglobin &lt; 100 g/L, platelet count &lt; 100 * 109 / L);

               9. liver function index (AST, ALT) a higher than normal amount of the upper limit
                  value of the three times (by myocardial infarction of liver function index
                  increase except);

              10. severe renal insufficiency (eGFR &lt; 30 mL/min / 1.73 m2) person;

              11. have heparin in thrombopenia interviewer;

              12. known to the research of the drugs and instruments allergy (common heparin,
                  bivalirudin aspirin and clopidogrel, stainless steel, contrast agents, etc.), or
                  those allergic constitution;

              13. pregnant women, lactation and planning of women patients;

              14. the researchers think that doesn't fit to participate in this study any
                  situation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Liang Zhenyang, Doctor</last_name>
    <phone>+862428897309</phone>
    <email>liangzhenyang@yahoo.com.cn</email>
  </overall_contact>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 8, 2013</lastchanged_date>
  <firstreceived_date>August 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling</investigator_full_name>
    <investigator_title>director of the department of cardiology</investigator_title>
  </responsible_party>
  <keyword>Bivalirudin</keyword>
  <keyword>Acute myocardio infarction</keyword>
  <keyword>PCI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
